William Blair Has Strong Forecast for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at William Blair upped their FY2024 earnings per share estimates for Tenax Therapeutics in a research note issued on Wednesday, November 13th. William Blair analyst M. Phipps now anticipates that the specialty pharmaceutical company will earn ($0.60) per share for the year, up from their prior estimate of ($6.90). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.93) EPS and FY2027 earnings at ($1.03) EPS.

TENX has been the subject of a number of other research reports. Leerink Partnrs raised Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. StockNews.com initiated coverage on Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating on the stock. Guggenheim assumed coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Leerink Partners started coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Trading Down 1.4 %

Shares of NASDAQ TENX opened at $4.87 on Monday. The firm’s 50 day moving average price is $3.99 and its 200-day moving average price is $3.69. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $41.92.

Institutional Trading of Tenax Therapeutics

Several hedge funds have recently modified their holdings of TENX. Sphera Funds Management LTD. bought a new stake in Tenax Therapeutics in the third quarter worth $101,000. Stonepine Capital Management LLC bought a new position in Tenax Therapeutics during the third quarter valued at $173,000. Finally, Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth $288,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.